EcoSynthetix Valuation
Is ECSN.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ECSN.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ECSN.F ($3.88) is trading above our estimate of fair value ($0.84)
Significantly Below Fair Value: ECSN.F is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ECSN.F?
Key metric: As ECSN.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is ECSN.F's PS Ratio? | |
|---|---|
| PS Ratio | 10.4x |
| Sales | US$15.95m |
| Market Cap | US$165.76m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 8.4x |
| Enterprise Value/EBITDA | -38.3x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does ECSN.F's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.9x | ||
ALTO Alto Ingredients | 0.1x | 3.1% | US$111.1m |
NANX Nanophase Technologies | 4x | n/a | US$190.5m |
NTIC Northern Technologies International | 1.5x | 8.1% | US$131.8m |
DNA Ginkgo Bioworks Holdings | 2.1x | 1.8% | US$461.8m |
ECSN.F EcoSynthetix | 10.4x | n/a | US$232.1m |
Price-To-Sales vs Peers: ECSN.F is expensive based on its Price-To-Sales Ratio (10.4x) compared to the peer average (1.9x).
Price to Sales Ratio vs Industry
How does ECSN.F's PS Ratio compare vs other companies in the US Chemicals Industry?
Price-To-Sales vs Industry: ECSN.F is expensive based on its Price-To-Sales Ratio (10.4x) compared to the US Chemicals industry average (1.5x).
Price to Sales Ratio vs Fair Ratio
What is ECSN.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 10.4x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate ECSN.F's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Ecora Resources
UK£162.8m
Operates as a natural resource royalty and streaming company in Australia, North and South America, Europe, and internationally.
ECRA.F
UK£0.84
7D
2.4%
1Y
-26.1%
CMOC Group
HK$159.3b
Engages in the mining, beneficiation, smelting, and refining of base and rare metals.
CMCL.F
HK$0.70
7D
-9.4%
1Y
27.9%
LyondellBasell Industries
US$27.1b
Operates as a chemical company in the United States, Germany, Mexico, Italy, Poland, France, Japan, China, the Netherlands, and internationally.
LYB
US$83.34
7D
-0.6%
1Y
-12.7%